VYNE – VYNE Therapeutics Inc.
VYNE Therapeutics Inc.VYNE
$2.70Name : VYNE Therapeutics Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $39,828,780.00
EPSttm : 3.29
VYNE Therapeutics Inc.
$2.70
4.65%$0.12Float Short %
0.48
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
0.29
EPS Last/This Y
2.78
EPS This/Next Y
Price
2.7
Target Price
6.19
Analyst Recom
1
Performance Q
24.42
Relative Volume
0.88
Beta
1.31
Ticker: VYNE
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-12-19 | VYNE | 2.41 | N/A | N/A | 0 |
| 2024-12-20 | VYNE | 2.55 | N/A | N/A | 0 |
| 2024-12-23 | VYNE | 2.57 | N/A | N/A | 0 |
| 2024-12-24 | VYNE | 2.97 | N/A | N/A | 0 |
| 2024-12-26 | VYNE | 3.2 | N/A | N/A | 0 |
| 2024-12-27 | VYNE | 3.1 | N/A | N/A | 0 |
| 2024-12-30 | VYNE | 3.13 | N/A | N/A | 0 |
| 2024-12-31 | VYNE | 3.34 | N/A | N/A | 0 |
| 2025-01-02 | VYNE | 3.33 | N/A | N/A | 0 |
| 2025-01-03 | VYNE | 3.44 | N/A | N/A | 0 |
| 2025-01-06 | VYNE | 4 | N/A | N/A | 0 |
| 2025-01-07 | VYNE | 4.28 | N/A | N/A | 0 |
| 2025-01-08 | VYNE | 3.94 | N/A | N/A | 0 |
| 2025-01-09 | VYNE | 3.92 | N/A | N/A | 0 |
| 2025-01-10 | VYNE | 3.44 | N/A | N/A | 0 |
| 2025-01-13 | VYNE | 3.02 | N/A | N/A | 0 |
| 2025-01-14 | VYNE | 2.71 | N/A | N/A | 0 |
| 2025-01-15 | VYNE | 2.71 | N/A | N/A | 0 |
| 2025-01-16 | VYNE | 2.58 | N/A | N/A | 0 |
| 2025-01-17 | VYNE | 2.71 | N/A | N/A | 0 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-12-19 | VYNE | 2.39 | - | - | 0.00 |
| 2024-12-20 | VYNE | 2.50 | - | - | 0.00 |
| 2024-12-23 | VYNE | 2.57 | - | - | 0.00 |
| 2024-12-24 | VYNE | 2.97 | - | - | 0.00 |
| 2024-12-26 | VYNE | 3.23 | - | - | 0.00 |
| 2024-12-27 | VYNE | 3.15 | - | - | 0.00 |
| 2024-12-30 | VYNE | 3.15 | - | - | 0.00 |
| 2024-12-31 | VYNE | 3.30 | - | - | 0.00 |
| 2025-01-02 | VYNE | 3.31 | - | - | 0.00 |
| 2025-01-03 | VYNE | 3.46 | - | - | 0.00 |
| 2025-01-06 | VYNE | 3.99 | - | - | 0.00 |
| 2025-01-07 | VYNE | 4.15 | - | - | 0.00 |
| 2025-01-08 | VYNE | 3.92 | - | - | 0.00 |
| 2025-01-09 | VYNE | 3.92 | - | - | 0.00 |
| 2025-01-10 | VYNE | 3.44 | - | - | 0.00 |
| 2025-01-13 | VYNE | 3.03 | - | - | 0.00 |
| 2025-01-14 | VYNE | 2.70 | - | - | 0.00 |
| 2025-01-15 | VYNE | 2.76 | - | - | 0.00 |
| 2025-01-16 | VYNE | 2.64 | - | - | 0.00 |
| 2025-01-17 | VYNE | 2.70 | - | - | 0.00 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-12-19 | VYNE | 0.00 | -11.63 | 0.51 |
| 2024-12-20 | VYNE | 0.00 | -11.63 | 0.51 |
| 2024-12-23 | VYNE | 0.00 | -11.63 | 0.51 |
| 2024-12-24 | VYNE | 0.00 | -11.63 | 0.51 |
| 2024-12-26 | VYNE | 0.00 | -11.63 | 0.49 |
| 2024-12-27 | VYNE | 0.00 | -11.63 | 0.49 |
| 2024-12-30 | VYNE | 0.00 | -11.63 | 0.49 |
| 2024-12-31 | VYNE | 0.00 | -11.63 | 0.49 |
| 2025-01-02 | VYNE | 0.00 | -11.63 | 0.49 |
| 2025-01-03 | VYNE | 0.00 | -11.63 | 0.49 |
| 2025-01-06 | VYNE | 0.00 | -11.63 | 0.49 |
| 2025-01-07 | VYNE | 0.00 | -11.63 | 0.49 |
| 2025-01-08 | VYNE | 0.00 | -11.63 | 0.49 |
| 2025-01-09 | VYNE | 0.00 | -11.63 | 0.49 |
| 2025-01-10 | VYNE | 0.00 | -11.63 | 0.49 |
| 2025-01-13 | VYNE | 0.00 | -11.63 | 0.48 |
| 2025-01-14 | VYNE | 0.00 | -11.63 | 0.48 |
| 2025-01-15 | VYNE | 0.00 | -11.63 | 0.48 |
| 2025-01-16 | VYNE | 0.00 | -11.63 | 0.48 |
| 2025-01-17 | VYNE | 0.74 | -11.63 | 0.48 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.29
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
0.74
Institutional Transactions
-11.63
Beta
1.31
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
21
Growth Score
25
Sentiment Score
26
Actual DrawDown %
99.5
Max Drawdown 5-Year %
-99.7
Target Price
6.19
P/E
Forward P/E
PEG
P/S
81.29
P/B
0.63
P/Free Cash Flow
EPS
-0.85
Average EPS Est. Cur. Y
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-6892.7
Relative Volume
0.88
Return on Equity vs Sector %
-72.6
Return on Equity vs Industry %
-60
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
VYNE Therapeutics Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 10
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
stock quote shares VYNE – VYNE Therapeutics Inc. Stock Price stock today
news today VYNE – VYNE Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VYNE – VYNE Therapeutics Inc. yahoo finance google finance
stock history VYNE – VYNE Therapeutics Inc. invest stock market
stock prices VYNE premarket after hours
ticker VYNE fair value insiders trading